Cytochroma uses state of the art science, expertise and robotics to deliver powerful models for drug discovery and development. Our technology predicts how drugs will react globally, in health and disease, reducing the need for animal testing, making drug development faster, safer and cheaper.
Cytochroma is a leading supplier of quality stem cell derived tissue worldwide. Our customers in the pharmaceutical, biotech, cosmetics and chemical/environmental industries rely on our robust, convenient and advanced solutions to make more informed decisions during discovery and development.
Our mission is to accelerate new drug development by providing leading industry research organisations with a renewable, reliable source of functional liver tissue.
Our unique, ethnically diverse library of human hepatocytes that enables a preview of how compounds will react at each phase of clinical trials.
We will shortly be piloting the following liver-specific disease models:
NAFLD - Lipid loaded mini-liver tissues that mimic the fatty liver phenotype of early stage non-alcoholic fatty liver disease.
NASH - Test progression of disease from steatosis to inflammation and fibrosis in the best 3D in vitro human model for NASH.
Fibrosis - Screen and test efficacy of anti-fibrotic drugs in our powerful 3D in vitro model that reflects scarring observed in human liver fibrosis.
Cholestasis - Investigate the detection of cholestatic potential in our 3D in vitro model.